Skin & Subcutaneous Tissue

DRESS syndrome: recognition and management

Clinical Overview and When to Suspect DRESS

— Aromatic anticonvulsants: carbamazepine, phenytoin, phenobarbital, lamotrigine, oxcarbazepine

— Allopurinol (especially in CKD, Han Chinese with HLA-B*58:01)

— Sulfonamides: sulfasalazine, TMP-SMX, dapsone

— Minocycline, vancomycin, abacavir (HLA-B*5701), nevirapine

Board pearl: The RegiSCAR criteria require ≥3 of: hospitalization, reaction suspected drug-related, acute rash, fever >38°C, lymphadenopathy ≥2 sites, ≥1 internal organ involved, lymphocytosis/lymphopenia, eosinophilia ≥0.7 ×10⁹/L or ≥10%, and thrombocytopenia.

Step 3 management trigger: Recognition of DRESS mandates immediate discontinuation of the culprit drug and admission — outpatient management is not appropriate. Do not "watch and wait" with topical steroids as you might for a benign morbilliform eruption; mortality risk is substantial.

DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a severe, idiosyncratic, delayed (T-cell mediated) hypersensitivity reaction with multi-organ involvement and mortality up to 10%, usually from hepatic or cardiac failure.

Latency is the signature feature: symptoms appear 2–8 weeks after starting the culprit drug — far longer than typical morbilliform rashes (4–14 days) or SJS/TEN (1–3 weeks).

Classic high-yield culprits (memorize):

Pathogenesis involves drug-specific T-cell activation plus reactivation of HHV-6 (most classic), HHV-7, EBV, or CMV — herpesvirus reactivation correlates with relapsing/protracted course.

When to suspect on Step 3: a patient on a new anticonvulsant, allopurinol, or sulfa drug for 3–6 weeks presents with fever, diffuse rash, facial edema, lymphadenopathy, and abnormal LFTs or eosinophilia. The combination of facial swelling + transaminitis + eosinophilia in a patient on a new drug is DRESS until proven otherwise.

Presentation Patterns and Key History

— Exact drug start date for every new medication in the past 8 weeks — DRESS latency commonly trips up clinicians who only review the past 1–2 weeks.

— Dose escalations (e.g., lamotrigine titration) and drug rechallenges.

— Prior reactions, family history of severe cutaneous adverse reactions (SCARs), and ethnic background (HLA pharmacogenomic risk).

— HIV status (nevirapine, abacavir, sulfa); gout (allopurinol); seizure disorder (anticonvulsants); chronic infection or autoimmune disease (sulfasalazine, minocycline).

— Hepatic: RUQ pain, jaundice, dark urine, nausea

— Renal: decreased urine output, edema

— Cardiac: chest pain, dyspnea, palpitations (myocarditis can present weeks after rash resolution)

— Pulmonary: cough, dyspnea (interstitial pneumonitis)

— Neurologic: headache, confusion (meningoencephalitis, rare)

— Endocrine: late thyroiditis or fulminant autoimmune type 1 diabetes months after recovery

Key distinction: Unlike SJS/TEN, DRESS lacks prominent mucosal erosions and epidermal detachment; mucositis if present is mild. Unlike acute generalized exanthematous pustulosis (AGEP), DRESS lacks dense pustules and has a much longer latency (weeks vs. <4 days).

Board pearl: Always ask explicitly "what medications did you start 6–8 weeks ago?" — patients rarely volunteer drugs they've taken "for over a month" as suspects.

Prodrome (1–2 days): low-grade fever, malaise, pruritus, pharyngitis, and lymphadenopathy — often mistaken for viral URI before rash develops.

Cutaneous phase: diffuse morbilliform eruption beginning on the trunk/upper extremities, becoming confluent and infiltrated. Involvement is typically >50% body surface area. Facial edema (especially periorbital) is present in ~75% and is a hallmark visual clue.

Systemic phase: high fevers (38.5–40°C), generalized lymphadenopathy, and organ-specific symptoms emerging over days to weeks.

Key history elements to elicit:

Organ-specific symptoms to probe:

Physical Exam Findings and Hemodynamic Assessment

— Confluent morbilliform/maculopapular eruption with infiltrated, edematous papules; may evolve to exfoliative erythroderma

— Facial edema — pathognomonic visual clue; eyelids swollen, cheeks puffy

— Occasional purpuric, targetoid, or vesicular areas; pustules can occur (overlap with AGEP)

— No frank epidermal detachment (negative Nikolsky) — its presence shifts diagnosis toward SJS/TEN

— Mucosal involvement mild (~25%); cheilitis or pharyngitis but not the hemorrhagic crusting of SJS/TEN

CCS pearl: On a CCS case, in addition to ordering "stop offending drug," your physical exam orders should explicitly include skin, lymph node, abdominal, cardiac, and neurologic exam — points are awarded for thorough multi-system assessment in a multi-organ disease.

Step 3 management: Hemodynamic instability in DRESS raises suspicion for fulminant myocarditis — obtain ECG, troponin, and echo even without classic chest pain; cardiac involvement may be silent and lethal.

Vital signs: fever (often 39–40°C), tachycardia proportional to fever, and occasionally hypotension suggestive of evolving sepsis-mimicking SIRS, myocarditis, or capillary leak — do not assume sepsis without considering DRESS-related hemodynamic compromise.

Skin exam:

Lymphatic: tender, mobile cervical/axillary/inguinal lymphadenopathy ≥2 sites is a RegiSCAR criterion.

Hepatic: hepatomegaly, RUQ tenderness, scleral icterus in severe hepatitis (the leading cause of DRESS-related death).

Cardiopulmonary: listen for new gallop, muffled heart sounds, friction rub (myocarditis/pericarditis); bibasilar crackles or hypoxia (pneumonitis).

Neurologic: meningismus or altered mental status warrants LP to evaluate for HHV-6 encephalitis.

Volume status: capillary leak and high fevers may produce relative hypovolemia; assess JVP, skin turgor, capillary refill, urine output.

Diagnostic Workup — Initial Labs, Imaging, ECG

— Eosinophilia ≥0.7 ×10⁹/L or ≥10% (present ~70–95%, may lag rash by 1–2 weeks)

— Atypical lymphocytes on smear (mononucleosis-like)

— Lymphocytosis or lymphopenia; thrombocytopenia in severe cases

— LFTs: hepatitis is the most common organ injury (~75–95%); pattern is typically hepatocellular (ALT > ALP) but can be cholestatic or mixed. ALT >5× ULN or bilirubin elevation portends severe disease.

— Creatinine and BUN: interstitial nephritis (~10–30%), more common with allopurinol and minocycline; check urine for eosinophils, WBC casts, mild proteinuria.

— ECG for conduction abnormalities, low voltage, ST changes

— Troponin and BNP/NT-proBNP at baseline and if symptoms develop

— Echocardiogram if any cardiac symptom, ECG change, or troponin elevation

Board pearl: A patient on allopurinol for 4 weeks with rash, eosinophilia 15%, AST 320, ALT 410, Cr 2.1 → DRESS with hepatitis + interstitial nephritis. Stop allopurinol; do not substitute febuxostat without dermatology/allergy input as cross-reactivity is uncommon but consequential.

Step 3 management: Order troponin and ECG at admission even without cardiac symptoms — myocarditis carries the highest acute mortality and may be clinically silent until decompensation.

CBC with differential — the diagnostic linchpin:

Comprehensive metabolic panel:

Cardiac workup (do not omit):

Inflammatory markers: CRP, ferritin (markedly elevated ferritin should prompt evaluation for HLH/MAS, a DRESS mimicker/complication).

CXR: assess for interstitial infiltrates (pneumonitis) and effusions; baseline for serial comparison.

TSH and glucose at baseline: thyroiditis and new-onset diabetes are well-documented late autoimmune sequelae — check at presentation and during follow-up.

Infectious workup to exclude mimics: blood cultures, hepatitis A/B/C serologies, HIV, EBV, CMV, and (if available) HHV-6 PCR.

Diagnostic Workup — Advanced or Confirmatory Studies

— Liver: ultrasound to exclude obstruction; biopsy rarely needed

— Kidney: urine microscopy, urine eosinophils (low sensitivity), consider biopsy if AKI severe or refractory

— Heart: cardiac MRI if myocarditis suspected and echo non-diagnostic; endomyocardial biopsy reserved for refractory/cardiogenic cases

— Lung: HRCT if hypoxia or persistent infiltrates

— CNS: MRI brain + LP (HHV-6 PCR in CSF) if encephalopathy

Key distinction: In vitro lymphocyte transformation test (LTT) can identify culprit drug but is research-tier and not required for management — never delay treatment awaiting LTT.

Board pearl: Patch testing is contraindicated during the acute phase — risk of flare. Defer to outpatient allergy/derm follow-up.

No single confirmatory test exists — DRESS is a clinical diagnosis supported by RegiSCAR scoring (definite ≥6, probable 4–5, possible 2–3) or the Japanese J-SCAR criteria (which require HHV-6 reactivation for "definite" DDRESS).

Skin biopsy: not diagnostic but useful to exclude SJS/TEN, AGEP, vasculitis. Findings are nonspecific — perivascular lymphocytic infiltrate with eosinophils, mild interface dermatitis, occasional necrotic keratinocytes.

HHV-6 PCR (whole blood): reactivation typically occurs 2–4 weeks into illness; supports diagnosis and predicts protracted/relapsing course. Also test HHV-7, EBV, CMV if course atypical or refractory.

Organ-specific advanced testing:

Patch testing: useful after recovery (≥6 months) to confirm culprit drug when multiple suspects exist; sensitivity ~30–60%, highest for anticonvulsants.

Pharmacogenomic HLA testing in select scenarios: HLA-B58:01 before allopurinol in Han Chinese, Thai, Korean populations; HLA-B5701 before abacavir (universal); HLA-B*15:02 before carbamazepine in Han Chinese/Southeast Asian patients.

Ferritin, triglycerides, fibrinogen, soluble IL-2R if HLH suspected (overlap with DRESS).

Risk Stratification and First-Line Management Logic

— Mild: rash + eosinophilia, LFTs <3× ULN, no other organ involvement → supportive care + high-potency topical steroids may suffice

— Moderate: LFTs 3–5× ULN, mild renal/pulmonary involvement, no hemodynamic compromise → systemic prednisone 0.5–1 mg/kg/day

— Severe: LFTs >5× ULN or hepatic synthetic dysfunction, AKI requiring dialysis, myocarditis, pneumonitis with hypoxia, encephalitis, HLH → IV methylprednisolone pulse (30 mg/kg/day × 3 days) and/or IVIG, cyclosporine, or rituximab

— Fluid resuscitation for capillary leak and fever-related losses

— Skin care: bland emollients, avoid trauma

— Nutritional support (high catabolic state)

— Empiric antibiotics only if culture-proven infection — avoid pre-emptive antibiotics, which add new drug exposures and may worsen reaction

— Avoid antipyretic NSAIDs if hepatitis; acetaminophen dose-limited

— Aromatic anticonvulsants cross-react (carbamazepine ↔ phenytoin ↔ phenobarbital ↔ oxcarbazepine) — switch to valproate, levetiracetam, topiramate, or gabapentin

— Sulfonamide antibiotics → non-sulfa alternative

— Allopurinol → consider febuxostat only after specialist input (rare cross-reactivity reported)

CCS pearl: On the CCS, order "discontinue [drug]" as your first action, then admit, then labs. Failing to stop the drug before initiating workup loses points and worsens simulated outcomes.

Step 3 management: Severity assessment drives steroid dose — do not default to a single regimen.

First and most important step: immediately discontinue the suspected culprit drug and all non-essential medications. Delay in withdrawal is the single strongest predictor of poor outcome.

Stratify severity to guide therapy intensity:

Admit all patients with confirmed or suspected DRESS — multi-organ failure can develop rapidly and unpredictably.

Supportive care priorities:

Avoid cross-reactive drug substitutions:

Pharmacotherapy — First-Line Drug Regimen

— Prednisone 0.5–1 mg/kg/day PO (or methylprednisolone IV equivalent) for moderate disease

— Methylprednisolone 30 mg/kg/day IV pulse × 3 days, then transition to oral prednisone 1 mg/kg/day for severe disease (myocarditis, severe hepatitis, encephalitis)

— Taper slowly over 8–12 weeks (sometimes 6 months) — rapid taper precipitates relapse, the most common pitfall

— IVIG 2 g/kg over 2–5 days — used in severe cases, especially with overlapping SJS/TEN features; evidence mixed

— Cyclosporine 3–5 mg/kg/day — emerging steroid-sparing option, particularly effective and avoids prolonged steroid morbidity

— Mycophenolate mofetil, cyclophosphamide, rituximab — case-series evidence for refractory cases

— Plasmapheresis — rare salvage for fulminant disease

Avoid:

— Empiric antibiotics without infection

— NSAIDs (hepatotoxic, may worsen renal injury)

— Allopurinol, anticonvulsants, sulfas if not the culprit (eliminate uncertainty)

Board pearl: Relapse during steroid taper is the most common complication of DRESS pharmacotherapy — anticipate it and taper over months, not weeks.

Step 3 management: When myocarditis is present, pulse methylprednisolone is preferred over oral prednisone — never under-treat cardiac involvement.

Systemic corticosteroids are first-line for moderate-to-severe DRESS, though no RCT confirms superiority — practice is guideline-based and expert-consensus-driven.

Standard regimen:

Topical high-potency corticosteroids (clobetasol 0.05%, betamethasone) BID to involved skin reduce cutaneous symptoms and may permit lower systemic doses in mild cases.

Steroid-sparing/adjunctive agents for steroid-refractory or steroid-dependent disease:

Antivirals: ganciclovir or valganciclovir for documented HHV-6/CMV reactivation with organ dysfunction (encephalitis, severe hepatitis). Not routine.

Symptomatic adjuncts: antihistamines for pruritus; acetaminophen (dose-adjusted) for fever.

Procedures and Expanded Pharmacology

— Confirm culprit drug truly stopped; review for hidden re-exposures (e.g., combination products)

— Increase steroid dose to last effective level, then slower taper

— Add cyclosporine 3–5 mg/kg/day (monitor BP, Cr, magnesium, drug levels) — steroid-sparing, often allows wean

— IVIG 2 g/kg if cyclosporine contraindicated or insufficient

— Test for HHV-6/CMV viremia; treat with ganciclovir if reactivation correlates with organ dysfunction

— Evaluate for HLH overlap: ferritin >10,000, cytopenias, splenomegaly — may require etoposide-based protocols

— Add culprit drug and all cross-reactive members to allergy list with reaction type ("DRESS — severe cutaneous reaction") — never label as "rash" only

— Report through FDA MedWatch; many institutions have SCAR registries

— Update electronic health record allergy module to fire interaction alerts

— Aromatic anticonvulsant DRESS → use levetiracetam, valproate, gabapentin, topiramate

— Allopurinol DRESS → urate-lowering options include lifestyle, losartan (mild uricosuric effect); febuxostat may be considered with specialist input

— Sulfonamide DRESS → avoid all sulfonamide antibiotics; non-antibiotic sulfonamides (furosemide, thiazides, sulfonylureas) generally tolerated but use cautiously

— Vancomycin DRESS → linezolid, daptomycin, ceftaroline as alternatives based on indication

CCS pearl: Add "document drug allergy with reaction type DRESS" as an explicit order; this prevents catastrophic rechallenge during future admissions.

Board pearl: Cross-reactivity among aromatic anticonvulsants is 40–80% — choose a non-aromatic alternative.

DRESS is non-procedural in management; expand pharmacologic and adjunctive strategies here.

Refractory or relapsing DRESS algorithm:

Drug labeling and registry:

Vaccination considerations: defer live vaccines during immunosuppression; resume routine vaccines after steroid taper.

Future drug exposures:

Desensitization is contraindicated in DRESS (unlike IgE-mediated reactions) — never rechallenge.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline risk due to polypharmacy (allopurinol, anticonvulsants for post-stroke seizures, sulfas)

— Higher mortality — reduced physiologic reserve, frequent cardiac and renal comorbidity, drug-drug interactions

— Atypical presentation: fever may be absent or low-grade; eosinophilia may be blunted by concurrent steroids or chemotherapy

— Steroid complications more frequent: hyperglycemia, osteoporosis fractures, delirium, GI bleeding — co-prescribe PPI, calcium/vitamin D, bisphosphonate consideration for prolonged courses

— Increased risk of steroid-induced psychosis and delirium — monitor mental status daily

— Allopurinol is the highest-risk drug; dose reduction by CrCl is mandatory (start 100 mg/day in CKD), and HLA-B*58:01 screening is indicated in high-risk ancestries

— Concurrent interstitial nephritis worsens drug clearance — adjust all renally cleared drugs (cyclosporine, valganciclovir)

— Avoid contrast and additional nephrotoxins during acute phase

— Monitor urine output, electrolytes (especially hyperkalemia if AKI), and consider early nephrology consult

— DRESS hepatitis itself can progress to acute liver failure — monitor INR, bilirubin, ammonia, mental status

— King's College or MELD criteria → early transplant center transfer if synthetic failure (INR >1.5, encephalopathy, bilirubin rising)

— Avoid hepatotoxic drugs (acetaminophen >2 g/day, statins, valproate, methotrexate)

— Dose-adjust prednisone metabolites and other hepatically cleared agents

Step 3 management: In an elderly patient with allopurinol DRESS + AKI, stop allopurinol immediately, hold ACE/ARBs, hold NSAIDs, fluid resuscitate, and consult nephrology — do not substitute febuxostat acutely.

Board pearl: Allopurinol DRESS mortality reaches 25% in elderly with CKD — the highest among DRESS subtypes.

Elderly patients:

Renal impairment:

Hepatic impairment:

Diabetics: steroid-induced hyperglycemia is universal; transition to sliding-scale or basal-bolus insulin; oral agents inadequate.

Special Populations — Pregnancy, Pediatrics, and Genetic Subgroups

— DRESS in pregnancy is rare but carries risk of fetal loss, preterm labor, IUGR, and rare neonatal DRESS-like syndrome via transplacental drug/metabolite

— Prednisone is preferred steroid (extensive placental metabolism; minimal fetal exposure) — use lowest effective dose

— Avoid cyclosporine in first trimester if possible; if needed (refractory), benefit may outweigh risk

— IVIG is considered safe in pregnancy

— Multidisciplinary care: MFM, dermatology, allergy

— Counsel on avoiding rechallenge in future pregnancies and labeling reaction in chart

— Most common culprits: anticonvulsants (carbamazepine, lamotrigine, phenobarbital), antibiotics (minocycline rare under 8 yo), sulfasalazine for JIA

— Lamotrigine DRESS risk increased by rapid titration and concurrent valproate (which inhibits lamotrigine metabolism) — always titrate lamotrigine slowly

— Late autoimmune thyroiditis and type 1 diabetes described in pediatric DRESS survivors — schedule TSH/glucose every 3 months for ≥1 year

— Steroid effects on growth — keep courses as short as feasible; cyclosporine-sparing strategies attractive

— HLA-B*58:01 + allopurinol → screen Han Chinese, Korean, Thai, African American populations

— HLA-B*15:02 + carbamazepine → screen Han Chinese, Southeast Asian; FDA labeling mandates testing

— HLA-B*5701 + abacavir → universal screening pre-prescription

— HLA-A*31:01 + carbamazepine → European/Japanese populations, broader SCAR spectrum

Key distinction: Lamotrigine DRESS in a child with concurrent valproate is a quintessential exam scenario — the interaction tripled lamotrigine levels.

Board pearl: HLA screening before allopurinol is standard of care in high-risk ethnicities — a Step 3 favorite preventive intervention.

Pregnancy:

Pediatrics:

HLA-defined subgroups (pharmacogenomic prevention):

HIV patients: increased risk of sulfa and nevirapine DRESS; CD4 < 200 increases risk.

Complications and Adverse Outcomes

— Fulminant hepatitis — leading cause of acute mortality; may require transplant

— Myocarditis — eosinophilic or hypersensitivity; can be silent, fatal, or relapse weeks after rash resolution; mortality up to 50% when present

— Interstitial nephritis with AKI — may require RRT; usually reversible

— Pneumonitis/ARDS — minocycline classically

— HLH/MAS overlap — hyperferritinemia, cytopenias, splenomegaly, hepatic dysfunction

— Encephalitis — often HHV-6-driven; altered mental status, seizures

— Hemodynamic collapse from capillary leak, sepsis-like SIRS, or cardiac failure

— Secondary infections during immunosuppression — bacteremia, opportunistic infections

— Relapse during steroid taper — most common; may resemble new DRESS flare

— Protracted course (months) with herpesvirus reactivation

— Autoimmune sequelae months to years later:

– Autoimmune thyroiditis (Graves or Hashimoto's, ~5%)

– Type 1 diabetes mellitus (fulminant, autoantibody-negative variants described)

– Lupus, autoimmune hepatitis, vitiligo, alopecia areata

— Chronic kidney disease from severe interstitial nephritis

— Persistent skin dyspigmentation or alopecia

Step 3 management: Schedule TSH and fasting glucose at 3, 6, and 12 months post-recovery — autoimmune endocrinopathies are the classic late sequela and a Step 3 follow-up favorite.

Board pearl: Cardiac involvement can present weeks after rash resolution — discharge counseling must include "return for chest pain, dyspnea, or palpitations for 3 months."

Acute complications (during initial 4–8 weeks):

Subacute and late complications:

Steroid-related complications: hyperglycemia, osteoporosis, infection, weight gain, mood changes, adrenal suppression on prolonged courses.

Mortality: overall 5–10%; higher with hepatic failure, myocarditis, elderly age, allopurinol culprit, delayed drug withdrawal.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Hemodynamic instability (MAP <65, vasopressor need)

— Myocarditis with EF reduction, arrhythmia, or troponin rise

— Acute liver failure (INR >1.5 with encephalopathy)

— Respiratory failure / ARDS / hypoxia requiring HFNC or mechanical ventilation

— AKI requiring CRRT

— Encephalitis with seizures or GCS decline

— Severe HLH/MAS

— Erythroderma >70% BSA with thermoregulatory failure (consider burn unit)

— Dermatology: confirm diagnosis, biopsy, guide topical therapy — consult at admission

— Allergy/Immunology: culprit identification, future avoidance, patch testing planning

— Hepatology: ALT >5× ULN, bilirubin >3, INR elevation, or hepatic encephalopathy

— Nephrology: AKI, persistent proteinuria, dialysis planning

— Cardiology: any cardiac symptom, ECG change, or troponin elevation

— Infectious disease: HHV-6/CMV reactivation, opportunistic infection on immunosuppression

— Pharmacy: comprehensive med reconciliation and cross-reactivity review

— Transplant center transfer: hepatic synthetic failure

— Inpatient steroid initiation → outpatient dermatology/allergy follow-up within 1–2 weeks

— Detailed discharge summary with culprit drug, cross-reactive class, taper schedule, and lab monitoring plan

— Patient and family education on relapse signs and red-flag symptoms

CCS pearl: On CCS, consult dermatology and allergy on admission day; obtain echo/troponin as standing orders; advance location to ICU if hemodynamics deteriorate.

Step 3 management: A DRESS patient developing new chest pain or dyspnea on hospital day 7 → repeat troponin, ECG, urgent echo, and cardiology consult — suspect myocarditis even if initial cardiac workup was normal.

All confirmed/suspected DRESS warrants admission — outpatient management is inappropriate given unpredictable multi-organ progression.

ICU admission criteria:

Subspecialty consults:

Transitions of care:

Key Differentials — Same-Category (Severe Cutaneous Adverse Reactions)

• Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN):
— Latency: 1–3 weeks (shorter than DRESS)
— Skin: dusky macules, targetoid lesions, epidermal detachment, positive Nikolsky; SJS <10% BSA, TEN >30%, overlap 10–30%
— Mucosa: severe hemorrhagic mucositis (oral, ocular, genital) — hallmark
— Systemic: fever, but less prominent eosinophilia and hepatitis than DRESS
— Same culprits: anticonvulsants, allopurinol, sulfas, NSAIDs (oxicams)
— Management: stop drug, burn-unit-level supportive care, ophthalmology, possible cyclosporine or etanercept
• Acute Generalized Exanthematous Pustulosis (AGEP):
— Latency: very short, <4 days (often <48 hours) — fastest of SCARs
— Skin: dense non-follicular sterile pustules on erythematous base, starting in flexures
— Systemic: fever, neutrophilia (not eosinophilia), usually no organ involvement
— Culprits: beta-lactams, macrolides, diltiazem, hydroxychloroquine
— Self-limited; resolves days after drug withdrawal
• Generalized fixed drug eruption: well-demarcated dusky plaques recurring at same site with rechallenge; minimal systemic features
• Erythema multiforme major: target lesions, often post-HSV, limited mucosal involvement, no eosinophilia
• SCAR overlap: DRESS-SJS overlap occurs; treat as the more severe phenotype
Key distinction table:
Feature	DRESS	SJS/TEN	AGEP
Latency	2–8 wk	1–3 wk	<4 days
Mucosa	Mild	Severe	Minimal
Eosinophilia	Yes	No	No
Hepatitis	Common	Mild	Rare
Detachment	No	Yes	No
Pustules	Possible	No	Dense
Board pearl: Facial edema + eosinophilia + transaminitis + 4-week latency = DRESS, not SJS or AGEP.
Step 3 management: Drug allergy documentation must specify reaction type — "rash" alone risks fatal rechallenge.

Key Differentials — Other-Category Causes

— Acute EBV/CMV mononucleosis: rash (especially after amoxicillin exposure), lymphadenopathy, atypical lymphocytes, hepatitis. Key differentiator: positive heterophile/EBV/CMV serologies, lacks facial edema, eosinophilia less prominent

— Acute HIV seroconversion: maculopapular rash, fever, lymphadenopathy, mucocutaneous ulcers — check HIV viral load and antigen-antibody

— Acute viral hepatitis: hepatitis A/B/C/E — serologies clarify

— Measles, parvovirus, dengue: epidemiologic context, specific serologies

— Bacteremia/septicemia with secondary rash — blood cultures, procalcitonin, lactate

— Toxic shock syndrome: hypotension, diffuse erythroderma, multi-organ involvement, strawberry tongue, late desquamation — Staph aureus or Strep pyogenes

Board pearl: Adult-onset Still's mimics DRESS but features neutrophilia, not eosinophilia, and the rash is evanescent (appears with fever, disappears). Ferritin is markedly elevated in both — use the differential count to distinguish.

Key distinction: Always include HIV testing in any patient with fever, rash, and lymphadenopathy.

Viral exanthems with hepatitis:

Sepsis with rash:

Kawasaki disease (pediatric): fever ≥5 days, conjunctivitis, mucositis, extremity changes, polymorphous rash, cervical lymphadenopathy — overlaps with DRESS clinically in children

Adult-onset Still's disease: quotidian fevers, salmon-pink evanescent rash, arthralgias, markedly elevated ferritin, leukocytosis (not eosinophilia)

Hemophagocytic lymphohistiocytosis (HLH): fever, splenomegaly, cytopenias, hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia — can overlap with DRESS

Hypereosinophilic syndrome: persistent eosinophilia >1.5 ×10⁹/L for >6 months with organ damage; no drug trigger

Cutaneous T-cell lymphoma (Sézary syndrome): erythroderma, lymphadenopathy, atypical lymphocytes (Sézary cells), chronic course — flow cytometry distinguishes

Acute graft-versus-host disease: post-transplant, rash + hepatitis + diarrhea

Autoimmune: SLE flare, dermatomyositis, vasculitis with skin/organ involvement — autoantibody panels

Secondary Prevention, Discharge Medications, Long-Term Plan

— Document allergy as "DRESS — life-threatening; do not rechallenge" in EHR

— Provide patient with a written list and MedicAlert bracelet

— Educate patient to recite culprit drug name and class at every healthcare visit

— Add cross-reactive members to allergy list (e.g., all aromatic anticonvulsants if carbamazepine was culprit)

— Slow prednisone taper over 8–12 weeks (or longer) with clear schedule and parameters for accelerating taper vs. holding

— PPI for GI prophylaxis during steroid course

— Calcium 1200 mg + vitamin D 800–1000 IU; bisphosphonate if prolonged course or osteoporosis risk

— Trimethoprim-sulfamethoxazole prophylaxis is contraindicated if sulfa was culprit; use atovaquone or dapsone (avoid dapsone if sulfa cross-reactive) for PCP prophylaxis when prednisone ≥20 mg for ≥4 weeks

— Insulin for steroid-induced hyperglycemia if needed

— Topical emollients, low-potency steroids for residual skin involvement

— Anticonvulsant DRESS → switch to non-aromatic (levetiracetam, valproate, gabapentin, topiramate)

— Allopurinol DRESS → lifestyle, urate-lowering with febuxostat only after specialist input

— Sulfasalazine DRESS → switch IBD/RA regimen (e.g., mesalamine without sulfa, methotrexate)

— Vancomycin DRESS → linezolid, daptomycin, ceftaroline

— Antiretroviral DRESS → genotype-guided alternative regimen

Step 3 management: Pneumocystis prophylaxis on prolonged high-dose steroids must use an agent that does not cross-react with the DRESS culprit — atovaquone is the safest universal default.

Board pearl: Relapse during taper is common — never taper faster than 10 mg/week below prednisone 20 mg.

Lifelong avoidance of the culprit drug and its cross-reactive class is the cornerstone:

Discharge medications:

Alternatives for the original indication:

Family counseling: first-degree relatives may share HLA risk — counsel about pharmacogenomic testing before high-risk drugs (especially carbamazepine, allopurinol, abacavir).

Follow-Up, Monitoring Parameters, Rehab, Counseling

— Week 1–2 post-discharge: PCP visit — CBC, CMP, repeat LFTs, BMP, vital signs, weight, BP, glucose

— Weekly labs during steroid taper for first month, then biweekly to monthly until off steroids

— Dermatology: 2–4 weeks for skin reassessment and confirmation of resolution

— Allergy/immunology: at 6 months for patch testing if culprit uncertain

— Endocrinology referral if any TSH/glucose abnormality

— Liver: AST, ALT, ALP, bilirubin, albumin, INR — weekly until normal, then monthly × 3

— Renal: Cr, BUN, urinalysis, urine protein/Cr — until baseline restored

— Cardiac: repeat ECG and consider echo at 4–6 weeks even if initial cardiac workup negative; counsel on cardiac red flags for 3 months

— Autoimmune surveillance: TSH and fasting glucose at 3, 6, 12 months and annually × 2 years; consider HbA1c; thyroid antibodies if symptoms

— Steroid-related: glucose, BP, weight, mood, bone density (DEXA if prolonged course)

— Drug-list literacy: patient should be able to name culprit and cross-reactive drugs unprompted

— Red-flag symptoms warranting immediate ER visit: new rash, fever, chest pain, dyspnea, jaundice, decreased urination, confusion

— Adherence to taper schedule — both rapid taper (relapse) and abrupt discontinuation (adrenal crisis) carry risk

— Vaccinations: defer live vaccines on prednisone ≥20 mg/day or ≥2 weeks; resume after taper

— Mental health support: post-SCAR PTSD and steroid-related mood disturbance are common — screen with PHQ-9

CCS pearl: Schedule follow-up at 1–2 weeks post-discharge and endocrine surveillance at 3, 6, 12 months as explicit orders.

Board pearl: Late-onset autoimmune type 1 diabetes can appear months after recovery — ongoing surveillance is mandatory.

Outpatient follow-up cadence:

Specific monitoring parameters:

Patient education and counseling:

Rehabilitation: physical therapy if prolonged ICU course; nutrition counseling for steroid weight gain; smoking cessation for cardiovascular optimization.

Ethical, Legal, and Patient Safety Considerations

— Failure to perform HLA-B*5701 testing before abacavir in any patient is a deviation from standard of care — universally indicated

— HLA-B*58:01 before allopurinol in Han Chinese, Korean, Thai, and African American patients is recommended by ACR; failure may constitute negligence in high-risk populations

— HLA-B*15:02 before carbamazepine in Han Chinese/Southeast Asian patients carries an FDA black box warning

— Document shared decision-making for high-risk drugs

— Always document reaction type (DRESS) and severity — never just "rash"

— Include cross-reactive drug classes in the allergy list

— Transitions of care (admission to floor, floor to ICU, discharge, transfer, primary care) are highest risk for rechallenge — emphasize verbal handoffs and medication reconciliation

— A patient with documented "sulfa allergy — DRESS" inadvertently prescribed sulfasalazine on transfer to rheumatology constitutes a never event with potential mortality

— Report SCARs through FDA MedWatch; many institutions have internal SCAR registries

— Notify outpatient pharmacy of allergy update

— HLA risk is shared by first-degree relatives — counsel about pharmacogenomic testing before they receive high-risk drugs; respect autonomy and confidentiality when discussing

— If DRESS resulted from preventable rechallenge or failure to screen HLA, transparent disclosure to patient/family is ethically required, including root-cause analysis and system improvements

— HLA testing access varies; advocate for insurance coverage in eligible populations

— Patients with limited English proficiency need translated allergy cards

Step 3 management: A patient discharged with "carbamazepine DRESS" returns to outpatient psychiatry, who prescribes oxcarbazepine — this is a preventable adverse event; psychiatrist must be educated on cross-reactivity within aromatic anticonvulsants, and EHR allergy alerts updated to include the class.

Informed consent and pharmacogenomic testing:

Drug allergy documentation and EHR safety:

Mandatory reporting:

Family counseling and confidentiality:

Disclosure of medical error:

Resource utilization and equity:

End-of-life considerations: in fulminant DRESS with multi-organ failure, early goals-of-care conversations with patient/family are essential.

High-Yield Associations and Rapid-Fire Clinical Facts

— HLA-B*5701 + abacavir (universal screening)

— HLA-B*58:01 + allopurinol (Han Chinese, Thai, Korean, African American)

— HLA-B*15:02 + carbamazepine (Han Chinese, Southeast Asian)

— HLA-A*31:01 + carbamazepine (European, Japanese)

Board pearl: A 30-year-old Han Chinese man with new-onset epilepsy on carbamazepine for 5 weeks with rash, facial edema, eosinophilia, and AST 400 → DRESS; HLA-B*15:02 screening should have been performed before prescribing.

Step 3 management: "Stop the drug first, then everything else."

Top 6 culprit drug categories (memorize): anticonvulsants (aromatic), allopurinol, sulfa antibiotics, minocycline, vancomycin, antiretrovirals (abacavir, nevirapine)

Latency: 2–8 weeks — DRESS distinguishing feature

Pathognomonic visual clue: facial edema (periorbital, cheek)

Hallmark labs: eosinophilia ≥10% or ≥0.7 ×10⁹/L, atypical lymphocytes, transaminitis

HHV-6 reactivation: most common, supports diagnosis, predicts relapse

Most common organ involvement: liver (75–95%); leading cause of mortality

Most lethal organ involvement: heart (myocarditis, can be silent and late)

RegiSCAR ≥6 = definite DRESS

Pharmacogenomic associations:

Aromatic anticonvulsant cross-reactivity: 40–80% — switch to levetiracetam, valproate, gabapentin, topiramate

Lamotrigine DRESS ↑ risk with rapid titration + concurrent valproate

Long-term sequelae: autoimmune thyroiditis (most common), type 1 diabetes, lupus, autoimmune hepatitis

Steroid taper duration: 8–12 weeks minimum, sometimes 6 months

Mortality: 5–10% overall; up to 50% with myocarditis

Always avoid: rechallenge, desensitization, cross-reactive drugs

DRESS vs. SJS/TEN: longer latency, less mucosa, more eosinophilia/hepatitis, no detachment

DRESS vs. AGEP: longer latency, eosinophilia (not neutrophilia), organ involvement

DRESS vs. Still's disease: eosinophilia in DRESS, neutrophilia in Still's; both have ferritin elevation

PCP prophylaxis on prolonged steroids: atovaquone (safe universal alternative if sulfa-allergic)

Allopurinol DRESS in CKD/elderly: highest mortality subtype

Drug allergy charting: always specify "DRESS", never just "rash"

Board Question Stem Patterns

Board pearl: When stems include facial edema + eosinophilia + 4–8 week drug latency, the answer is always DRESS.

Step 3 management: First answer choice is stop the drug — virtually always correct first action.

Stem 1 — Allopurinol DRESS in elderly CKD: 72-year-old man, gout, started allopurinol 6 weeks ago, now febrile, diffuse rash, facial edema, eosinophilia 18%, AST 380, Cr 2.4 (baseline 1.3). Best next step? → Discontinue allopurinol, admit, initiate systemic corticosteroids. Distractors: continue allopurinol with antihistamines; substitute febuxostat; start broad-spectrum antibiotics.

Stem 2 — Carbamazepine DRESS in Han Chinese patient: 28-year-old Taiwanese woman started carbamazepine 5 weeks ago for trigeminal neuralgia; now fevers, rash, lymphadenopathy, ALT 520. Question 1: What was the preventable measure? → HLA-B*15:02 screening before initiation. Question 2: Acceptable substitute? → levetiracetam or gabapentin, NOT oxcarbazepine or phenytoin.

Stem 3 — Lamotrigine DRESS with valproate interaction: 14-year-old on valproate for epilepsy, lamotrigine added with rapid titration 4 weeks ago, now DRESS. Mechanism? → Valproate inhibits lamotrigine glucuronidation, raising levels; rapid titration further increased risk.

Stem 4 — Late myocarditis: DRESS patient improving 3 weeks into hospitalization develops chest pain and dyspnea; troponin elevated, EF 30%. Diagnosis? → DRESS-associated myocarditis. Management? → IV pulse methylprednisolone, cardiology consult, ICU monitoring.

Stem 5 — HHV-6 reactivation: DRESS patient on prednisone for 2 weeks develops worsening fever, encephalopathy, LFTs trending up. Next test? → HHV-6 PCR (and CMV/EBV). Treat with valganciclovir if positive with organ dysfunction.

Stem 6 — Late autoimmune sequela: 6 months after DRESS recovery, patient presents with polyuria, polydipsia, weight loss, glucose 480, ketonuria. Diagnosis? → Autoimmune type 1 diabetes (DRESS late sequela). Highlights importance of scheduled TSH/glucose follow-up.

Stem 7 — PCP prophylaxis in sulfa-DRESS: Patient with TMP-SMX DRESS on prednisone 40 mg/day for 8 weeks. Best PCP prophylaxis? → Atovaquone, NOT TMP-SMX or dapsone.

Stem 8 — Patch testing timing: Patient recovered from DRESS, multiple suspect drugs. When to patch test? → At least 6 months after resolution, not acutely.

One-Line Recap

DRESS is a delayed (2–8 weeks), T-cell-mediated, multi-organ drug hypersensitivity reaction defined by fever, morbilliform rash with facial edema, lymphadenopathy, eosinophilia, and visceral involvement (especially hepatitis), whose management hinges on immediate culprit withdrawal, systemic corticosteroids titrated to severity, lifelong avoidance of the drug and cross-reactive class, and longitudinal surveillance for late autoimmune sequelae.

Board pearl: Stop the drug first, treat the organs second, document the allergy third, and surveil for autoimmunity for years.

Recognition: 2–8 week latency + facial edema + eosinophilia + transaminitis + lymphadenopathy → DRESS until proven otherwise; top culprits are aromatic anticonvulsants, allopurinol, sulfas, minocycline, vancomycin, and abacavir/nevirapine.

Acute management: stop the drug immediately, admit, evaluate all organs (LFTs, Cr, troponin/ECG/echo, CXR, ferritin), initiate prednisone 0.5–1 mg/kg/day (or methylprednisolone pulse for severe disease — myocarditis, hepatic failure, encephalitis), and taper slowly over 8–12 weeks to prevent relapse.

Prevention and long-term care: document allergy as "DRESS — life-threatening" with cross-reactive class in EHR; use HLA pharmacogenomic screening (B5701/abacavir, B58:01/allopurinol, B*15:02/carbamazepine) before high-risk drugs in at-risk populations; choose non-cross-reactive alternatives; use atovaquone for PCP prophylaxis if sulfa was culprit.

Follow-up cadence: weekly labs during taper, dermatology and allergy follow-up, and TSH plus fasting glucose at 3, 6, and 12 months to detect autoimmune thyroiditis or type 1 diabetes — the signature delayed sequelae that distinguish DRESS from all other drug eruptions and that Step 3 examiners love to test.